Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Influenza

Free Subscription 27.10.2025 1 Antiviral Res 2 BMC Pediatr 1 Cell 1 Epidemiol Infect 1 J Clin Microbiol 1 J Gen Virol 4 J Infect 10 J Virol 4 J Virol Methods 3 Lancet 2 N Engl J Med 9 PLoS One 1 Proc Natl Acad Sci U S A 10 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Antiviral Res

1. BESSONNE M, Morel J, Nevers Q, Groutsch J, et al
   Inhibition of influenza virus replication by artificial proteins (alphaReps) targeting its RNA-polymerase.
   Antiviral Res. 2025 Oct 21:106300. doi: 10.1016/j.antiviral.2025.106300.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

2. WONG K, Ducharme R, Murphy MSQ, Clarke AE, et al
   SARS-CoV-2 infection in pregnancy and infant outcomes in the first year of life: a retrospective cohort study.
   BMC Pediatr. 2025;25:842.
   PubMed         Abstract available
   
   
3. MAGGIO ABR, Palomo S, Joye R, Huguet H, et al
   Reduced aerobic capacity in children with multisystem inflammatory syndrome in children (MIS-C) after PICU admission: a retrospective cohort study, 2020-2022.
   BMC Pediatr. 2025;25:835.
   PubMed         Abstract available
   
   

   
   Cell

4. HICKMAN HD, Moutsopoulos NM
   Don't forget to floss! An innovative approach for vaccine delivery.
   Cell. 2025;188:5787-5789.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

5. GODOY P, Pardos J, Garcia Cenoz M, Parron I, et al
   Mask wearing by COVID-19 index cases reduces SARS-CoV-2 transmission to household contacts.
   Epidemiol Infect. 2025;153:e125.
   PubMed         Abstract available
   
   

   
   J Clin Microbiol

6. BACSIK DJ, Mills MG, Monroe LD, Spring C, et al
   Validation of H5 influenza virus subtyping RT-qPCR assay and low prevalence of H5 detection in 2024-2025 influenza virus season.
   J Clin Microbiol. 2025 Oct 21:e0041525. doi: 10.1128/jcm.00415.
   PubMed         Abstract available
   
   

   
   J Gen Virol

7. SHIMOTAI Y, Sugawara K, Matsuzaki Y, Muraki Y, et al
   Cytoplasmic domain of CM2 is involved in the replication of influenza C virus.
   J Gen Virol. 2025;106:002165.
   PubMed         Abstract available
   
   

   
   J Infect

8. MOORE CM, Secor EA, Fairbanks-Mahnke A, Everman JL, et al
   Independent and interactive effects of viral species on early-life lower respiratory tract illness.
   J Infect. 2025 Sep 25:106616. doi: 10.1016/j.jinf.2025.106616.
   PubMed         Abstract available
   
   
9. RAJAN A, Nagaraj D, Bomidi C, Aloisio GM, et al
   Single cell sequencing analysis of respiratory syncytial virus-infected pediatric and adult human nose organoids reveals age differences, proliferative diversity and identifies novel cellular tropism.
   J Infect. 2025;91:106617.
   PubMed         Abstract available
   
   
10. GRANVIK C, Persson IL, Barros GWF, Ahlm C, et al
    Long-term Physical Capacity Following COVID-19: A Prospective, Three-Year Study.
    J Infect. 2025 Sep 12:106614. doi: 10.1016/j.jinf.2025.106614.
    PubMed         Abstract available
    
    
11. PRITCHARD E, Vihta KD, Lipworth S, Pouwels KB, et al
    An Electronic Health Record-Wide Association Study to identify populations at increased risk of E. coli bloodstream infections.
    J Infect. 2025 Sep 3:106612. doi: 10.1016/j.jinf.2025.106612.
    PubMed         Abstract available
    
    

    
    J Virol

12. JOSEPH R, Marais G, Iranzadeh I, Alisoltani A, et al
    Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.
    J Virol. 2025 Sep 5:e0078025. doi: 10.1128/jvi.00780.
    PubMed         Abstract available
    
    
13. WANG J, Sang X, Zheng W, Chan JF-W, et al
    Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.
    J Virol. 2025 Sep 15:e0065825. doi: 10.1128/jvi.00658.
    PubMed         Abstract available
    
    
14. FARRUKEE R, Mordant F, Mackenzie-Kludas C, Mesner D, et al
    Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2.
    J Virol. 2025 Sep 15:e0082325. doi: 10.1128/jvi.00823.
    PubMed         Abstract available
    
    
15. RZYMSKI P, Poniedzialek B, Zarebska-Michaluk D, Tomasiewicz K, et al
    High seroprevalence and high risk: why are older adults more prone to respiratory syncytial virus?
    J Virol. 2025;99:e0143225.
    PubMed         Abstract available
    
    
16. CHIOK KL, Jenik K, Fenton M, Falzarano D, et al
    MERS-CoV and SARS-CoV-2 infection in diverse human lung organoid-derived cultures.
    J Virol. 2025 Sep 18:e0109825. doi: 10.1128/jvi.01098.
    PubMed         Abstract available
    
    
17. HAMMER E, Flynn C, Rossler J, Erder J, et al
    Prediction of COVID-19 disease progression by multiparametric analysis of circulating extracellular vesicles with flow cytometry.
    J Virol. 2025 Sep 23:e0118925. doi: 10.1128/jvi.01189.
    PubMed         Abstract available
    
    
18. TSUJINO S, Tsuda M, Nao N, Okumura K, et al
    Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.
    J Virol. 2025 Sep 23:e0090825. doi: 10.1128/jvi.00908.
    PubMed         Abstract available
    
    
19. SHU T, Wang X, Li Y, Su J, et al
    Respiratory syncytial virus phosphoprotein has NTPase and helicase-like activities.
    J Virol. 2025;99:e0099625.
    PubMed         Abstract available
    
    
20. SUN L, Huang M, Feng S, Zhang W, et al
    Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
    J Virol. 2025 Sep 30:e0120925. doi: 10.1128/jvi.01209.
    PubMed         Abstract available
    
    
21. PAN Z, Jiang L, Chen Y, Peng H, et al
    Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.
    J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099.
    PubMed         Abstract available
    
    

    
    J Virol Methods

22. AFZAL M, Willcox MDP, Praet S, Mcdonald M, et al
    Evaluating the effectiveness of a novel environmental decontamination system utilizing low-energy hyper-charged photoelectrons against coronavirus.
    J Virol Methods. 2026;339:115269.
    PubMed         Abstract available
    
    
23. HINOJOSA-TRUJILLO D, Dehesa-Canseco F, Garcia-Vega M, Mata-Haro V, et al
    Evaluation of two IgG-scFv bispecific antibodies for neutralizing Omicron variants of SARS-CoV-2.
    J Virol Methods. 2026;339:115258.
    PubMed         Abstract available
    
    
24. BRAVI ME, Fuentealba NA, Brasso N, Sguazza GH, et al
    Performance evaluation of a SYBR Green-based real-time quantitative PCR for SARS-CoV-2 detection from animal oropharyngeal samples.
    J Virol Methods. 2026;339:115259.
    PubMed         Abstract available
    
    
25. CHEN Y, Zhang T, Zhang J, Dong X, et al
    Comparative effects of three SARS-CoV-2 inactivation methods on cytokine detection using LEGENDplex bead-based immunoassays.
    J Virol Methods. 2026;339:115244.
    PubMed         Abstract available
    
    

    
    Lancet

26. 
    Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed         Abstract available
    
    
27. 
    Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed         Abstract available
    
    
28. JOHANSEN ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, et al
    Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
    Lancet. 2025 Oct 17:S0140-6736(25)01742-8. doi: 10.1016/S0140-6736(25)01742.
    PubMed         Abstract available
    
    

    
    N Engl J Med

29. SIEGERS JY, Xie R, Edwards KM, Byrne AMP, et al
    Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia.
    N Engl J Med. 2025;393:1650-1652.
    PubMed        
    
    
30. CAI M, Xie Y, Al-Aly Z
    Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
    N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
    PubMed         Abstract available
    
    

    
    PLoS One

31. HEMATRAM YADAV RY, Thangiah N, Bhaskaran KS, Kumarasamy C, et al
    Factors associated with hospitalization of people with influenza in a Malaysian tertiary hospital from 2015 to 2019.
    PLoS One. 2025;20:e0333921.
    PubMed         Abstract available
    
    
32. ABIDIN FA, Prathama AG, Fitriana E, Mayangsari A, et al
    Depression, anxiety, and stress levels during the COVID-19 pandemic: A longitudinal study among Indonesian psychologists.
    PLoS One. 2025;20:e0315584.
    PubMed         Abstract available
    
    
33. CATALFAMO CJ, Jacobs ET, Falk LP, Lauro P, et al
    Concordance between self-reported SARS-CoV-2 positivity and laboratory-confirmed positivity.
    PLoS One. 2025;20:e0334102.
    PubMed         Abstract available
    
    
34. KALIA V, Knauft K
    Adults with adverse childhood experiences report greater coronavirus anxiety.
    PLoS One. 2025;20:e0323401.
    PubMed         Abstract available
    
    
35. KUCHLER J, Zinnecker T, Hellwig P, Wolf M, et al
    Quantitative analysis of proteomic changes in two monoclonal suspension MDCK cell lines infected with human influenza A virus (H1N1).
    PLoS One. 2025;20:e0327939.
    PubMed         Abstract available
    
    
36. HOLZER A, Stoever A, Lau M, Gleich S, et al
    Quantitative and qualitative changes in substance-related administrative offences in road traffic during the SARS-CoV-2 pandemic in Munich.
    PLoS One. 2025;20:e0334598.
    PubMed         Abstract available
    
    
37. BALECH B, Lo Presti A, Telegrafo C, Maisto L, et al
    Investigating the evolutionary dynamics and mutational pattern of SARS-CoV-2 spike gene on selected SARS-CoV-2 variants.
    PLoS One. 2025;20:e0333093.
    PubMed         Abstract available
    
    
38. MAKI K
    Methodology for predicting hospital admissions and evaluating recovery rates for coronavirus disease in Japan.
    PLoS One. 2025;20:e0334643.
    PubMed         Abstract available
    
    
39. DELAVARY M, Kalantari AH, Farsangi H, Mohammadzadeh Moghaddam A, et al
    Effect of COVID-19 restrictions and fuel prices on traffic volume and offenses in Iran: A spatiotemporal analysis.
    PLoS One. 2025;20:e0332443.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

40. FORMIGA RO, Pesenti L, de la Heronniere FC, Ladjemi MZ, et al
    Cytosolic proliferating cell nuclear antigen (PCNA) orchestrates neutrophil hyperactivation in COVID-19.
    Proc Natl Acad Sci U S A. 2025;122:e2503667122.
    PubMed         Abstract available
    
    

    
    Vaccine

41. CHAUDHRY T, Tum P, Morrow F, Hargreaves S, et al
    Facilitators to strengthening vaccine uptake post-pandemic amongst underserved populations considering social norms and health beliefs: a global systematic review.
    Vaccine. 2025;65:127769.
    PubMed         Abstract available
    
    
42. ZEEVAT F, Luttjeboer J, Korsten K, van Boven M, et al
    Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands.
    Vaccine. 2025;65:127735.
    PubMed         Abstract available
    
    
43. CAMPBELL PM, Ess GJ, Lale A, Talaat KR, et al
    Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews.
    Vaccine. 2025;65:127781.
    PubMed         Abstract available
    
    
44. DOMINGUEZ ISLAS CP, Magaret CA, Molitor C, Serebryannyy L, et al
    SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines.
    Vaccine. 2025;65:127738.
    PubMed         Abstract available
    
    
45. OPHIR Y, Wong JH, Haddad KR, Huuskonen A, et al
    Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1.
    Vaccine. 2025;65:127784.
    PubMed         Abstract available
    
    
46. WROBLEWSKI M, Meler A
    Vaccine acceptance and refusal in Western and Central and Eastern European countries: An analysis based on the European Social Survey data from 23 countries, using a classification and regression tree.
    Vaccine. 2025;65:127807.
    PubMed         Abstract available
    
    
47. FANG X, Holding AC, Audet EC, Thai H, et al
    Understanding COVID-19 vaccination disparity among Black adults in North America: A two-study motivational approach.
    Vaccine. 2025;65:127803.
    PubMed         Abstract available
    
    
48. OGATA T, Hattori S, Kawachi K, Ishikane M, et al
    Durability of effectiveness of a booster dose of COVID-19 bivalent (ancestral/BA.4-5) vaccine against all-cause mortality in older adults in Japan, October 2022 to September 2023.
    Vaccine. 2025;65:127796.
    PubMed         Abstract available
    
    
49. HIRAGA K, Momose H, Kuribayashi W, Uemura M, et al
    Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.
    Vaccine. 2025;65:127805.
    PubMed         Abstract available
    
    
50. BLADH O, Aguilera K, Sheikh-Mohamed S, Nardulli J, et al
    Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries.
    Vaccine. 2025;65:127792.
    PubMed         Abstract available
    
    

    
    Virology

51. TSUNEKI-TOKUNAGA A, Komatsu M, Perdana WY, Nishiyama S, et al
    Epidemic influenza virus strains with high growth capability induce severe inflammatory response in vivo.
    Virology. 2025;613:110717.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.